Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck

References

• Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int. J. Cancer97, 72–81 (2002).
   PubMed Web of Science ®Google Scholar
• Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N. Engl. J. Med.328, 184–194 (2003).
   Google Scholar
• Vaidya AM, Petruzzelli GJ, Clark J, Emami B. Patterns of spread in recurrent head and neck squamous cell carcinoma. Otolaryngol. Head Neck Surg.125(4), 393–396 (2001).
   PubMedGoogle Scholar
• Woolgar JA, Rogers S, West CR, Errington RD, Brown JS, Vaughan ED. Survival and patterns of recurrence in 200 oral cancer patients treated by radical surgery and neck dissection. Oral Oncol.35(3), 257–265 (1999).
   PubMedGoogle Scholar
• Yuen AP, Ho CM, Wei WI, Lam LK. Analysis of recurrence after surgical treatment of advanced laryngeal carcinoma. J. Laryngol. Otol.109(11), 1063–1067 (1995).
   PubMedGoogle Scholar
• Zbären P, Caversaccio M, Thoeny HC, Nuyens M, Curschmann J, Stauffer E. Radionecrosis or tumor recurrence after radiation of laryngeal and hypopharyngeal carcinomas. Otolaryngol. Head Neck Surg.135(6), 838–843 (2006).
   PubMedGoogle Scholar
• Zbären P, Weidner S, Thoeny HC. Laryngeal and hypopharyngeal carcinomas after (chemo)radiotherapy: a diagnostic dilemma. Curr. Opin. Otolaryngol. Head Neck Surg.16(2), 147–153 (2008).
   PubMed Web of Science ®Google Scholar
• Lonneux M, Lawson G, Ide C, Bausart R, Remacle M, Pauwels S. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope110(9), 1493–1497 (2000).
   PubMed Web of Science ®Google Scholar
• Abgral R, Querellou S, Potard G et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? J. Nucl. Med.50(1), 24–29 (2009).
   PubMedGoogle Scholar
• Wang Y-F, Liu R-S, Chu P-Y et al. Positron emission tomography in surveillance of head and neck squamous cell carcinoma after definitive chemoradiotherapy. Head Neck31(4), 442–451 (2009).
   PubMedGoogle Scholar
• AlvarezPérez RM, Borrego Dorado I, Ruiz Franco-Baux JV, Vázquez Albertino RJ. [Evaluation of efficacy and clinical impact of positron emission tomography with 18F fluoro-deoxyglucose in patients with suspicion of recurrent head and neck cancer or distant metastases]. Rev. Esp. Med. Nucl.26(1), 30–39 (2007).
   PubMedGoogle Scholar
• Salaun PY, Abgral R, Querellou S et al. Does 18fluoro-fluorodeoxyglucose positron emission tomography improve recurrence detection in patients treated for head and neck squamous cell carcinoma with negative clinical follow-up? Head Neck29(12), 1115–1120 (2007).
   PubMedGoogle Scholar
• Goerres GW, Schmid DT, Bandhauer F et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch. Otolaryngol. Head Neck Surg.130(1), 105–109 (2004).
   PubMedGoogle Scholar
• Kubota K, Yokoyama J, Yamaguchi K et al. FDG-PET delayed imaging for the detection of head and neck cancer recurrence after radio-chemotherapy: comparison with MRI/CT. Eur. J. Nucl. Med. Mol. Imag.31(4), 590–595 (2004).
   PubMedGoogle Scholar
• Fischbein NJ, AAssar OS, Caputo GR et al. Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck. Am. J. Neuroradiol.19, 1189–1196 (1998).
   PubMedGoogle Scholar
• Wong RJ, Lin DT, Schoder H et al. Diagnostic and prognostic value of [18F] fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J. Clin. Oncol.20, 4199–4208 (2002).
   PubMed Web of Science ®Google Scholar
• Kunkel M, Forster GJ, Reichert TE et al. Detection of recurrent oral squamous cell carcinoma by [18F]-2-fluorodeoxyglucose-positron emission tomography: implications for prognosis and patient management. Cancer98, 2257–2265 (2003).
   PubMedGoogle Scholar
• Kitagawa Y, Nishizawa S, Sano K et al. Prospective comparison of FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J. Nucl. Med.44, 198–206 (2003).
   PubMedGoogle Scholar
• Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur. J. Nucl. Med.26, 767–773 (1999).
   PubMedGoogle Scholar
• Terhaard CH, Bongers V, van Rijk PP, Hordijk GJ. F-18-fluoro-deoxy-glucose positron-emission tomography scanning in detection of local recurrence after radiotherapy for laryngeal/pharyngeal cancer. Head Neck23, 933–941 (2001).
   PubMedGoogle Scholar
• Ryan WR, Fee WE Jr, Le QT, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope115(4), 645–650 (2005).
   PubMedGoogle Scholar
• Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger MJ. Clinical applications of FDG PET and PET/CT in head and neck cancer. J. Oncol.2009, 208725 (2009).
   PubMedGoogle Scholar
• Wong RJ. Current status of FDG-PET for head and neck cancer. J. Surg. Oncol.97(8), 649–52 (2008).
   PubMedGoogle Scholar
• Srinivasan A, Dvorak R, Perni K, Rohrer S, Mukherji SK. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am. J. Neuroradiol.29(1), 40–44 (2008).
   PubMedGoogle Scholar
• Vandecaveye V, de Keyzer F, Van der Poorten V et al. Evaluation of the larynx for tumour recurrence by diffusion-weighted MRI after radiotherapy: initial experience in four cases. Br. J. Radiol.79, 681–687 (2006).
   PubMedGoogle Scholar
• Ghosh SK, Roland NJ, Kumar A et al. Detection of synchronous lung tumors in patients presenting with squamous cell carcinoma of the head and neck. Head Neck31(12), 1563–1570 (2009).
   PubMedGoogle Scholar
• Laccourreye O, Veivers FD, Hans S, Brasnu FD, Garcia D, Laccourreye FL. Metachronous second primary cancers after successful partial laryngectomy for invasive squamous cell carcinoma of the true vocal cord. Ann. Otol. Rhinol. Laryngol.111(3 Pt 1), 204–209 (2002).
   PubMedGoogle Scholar
• Douglas WG, Rigual NR, Loree TR, Wiseman SM, Al-Rawi S, Hicks WL Jr. Current concepts in the management of a second malignancy of the lung in patients with head and neck cancer. Curr. Opin. Otolaryngol. Head Neck Surg.11(2), 85–88 (2003).
   PubMedGoogle Scholar
• Bradley PJ, Bradley PT. Searching for metachronous tumours in patients with head and neck cancer: the ideal protocol! Curr. Opin. Otolaryngol. Head Neck Surg.18(2), 124–133 (2010).
   PubMedGoogle Scholar
• Mercer RR, Lucas NC, Simmons AN et al. Molecular discrimination of multiple primary versus metastatic squamous cell cancers of the head/neck and lung. Exp. Mol. Pathol.86(1), 1–9 (2009).
   PubMedGoogle Scholar
• Pivot X, Niyikiza C, Poissonnet G et al. Clinical prognostic factors for patients with recurrent head and neck cancer: implications for randomized trials. Oncology61(3), 197–204 (2001).
   PubMed Web of Science ®Google Scholar
• Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer101(10), 2222–2229 (2004).
   PubMed Web of Science ®Google Scholar
• Campbell JB, Dorman EB, Helliwell TR et al. Factors predicting response of end stage squamous cell carcinoma of the head and neck to cisplatinum. Clin. Otolaryngol. Allied Sci.12(3), 167–176 (1987).
   PubMedGoogle Scholar
• Amer MH, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer43(6), 2202–2206 (1979).
   PubMedGoogle Scholar
• Penel N, Berthon C, Everard F et al. Prognosis of hypercalcemia in aerodigestive tract cancers: study of 136 recent cases. Oral Oncol.41(9), 884–889 (2005).
   PubMedGoogle Scholar
• de Graeff A, de Leeuw JR, Ros WJ, Hordijk GJ, Blijham GH, Winnubst JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur. J. Cancer37(3), 332–339 (2001).
   PubMed Web of Science ®Google Scholar
• Fakhry C, Westra WH, Li S, Cmelak A et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl Cancer Inst.100(4), 261–269 (2008).
   PubMed Web of Science ®Google Scholar
• Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope110(3 Pt 2 Suppl. 93), 1–18 (2000).
   PubMed Web of Science ®Google Scholar
• Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J. Clin. Oncol.24(17), 2653–2658 (2006).
   PubMed Web of Science ®Google Scholar
• Haraf DJ, Weichselbaum RR, Vokes EE. Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann. Oncol.7, 913–918 (1996).
   PubMedGoogle Scholar
• De Crevoisier R, Bourhis J, Domenge C et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave–Roussy Institute in a series of 169 patients. J. Clin. Oncol.16, 3556–3562 (1998).
   PubMed Web of Science ®Google Scholar
• Ohizumi Y, Tamai Y, Imamiya S et al. Prognostic factors of reirradiation for recurrent head and neck cancer. Am. J. Clin. Oncol.25, 408–413 (2002).
   PubMedGoogle Scholar
• Spencer SA, Harris J, Wheeler RH et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int. J. Radiat. Oncol. Biol. Phys.51, 1299–1304 (2001).
   PubMed Web of Science ®Google Scholar
• Spencer SA, Harris J, Wheeler RH et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck30(3), 281–288 (2008).
   PubMed Web of Science ®Google Scholar
• Langer CJ, Harris J, Horwitz EM et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J. Clin. Oncol.25(30), 4800–4805 (2007).
   PubMed Web of Science ®Google Scholar
• Salama JK, Vokes EE, Chmura SJ et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys.64, 382–391 (2006).
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Padhya T, McCaffrey J et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J. Clin. Oncol.27, 1983–1991 (2009).
   PubMed Web of Science ®Google Scholar
• Sulman EP, Schwartz DL, Le TT et al. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int. J. Radiat. Oncol. Biol. Phys.73(2), 399–409 (2009).
   PubMed Web of Science ®Google Scholar
• Daiko H, Nagai K, Yoshida J et al. The role of pulmonary resection in tumors metastatic from head and neck carcinomas. Jpn J. Clin. Oncol.40(7), 639–644 (2010).
   PubMed Web of Science ®Google Scholar
• Shiono S, Kawamura M, Sato T et al.; Metastatic Lung Tumor Study Group of Japan. Pulmonary metastasectomy for pulmonary metastases of head and neck squamous cell carcinomas. Ann. Thorac. Surg.88(3), 856–860 (2009).
   PubMed Web of Science ®Google Scholar
• Wedman J, Balm AJ, Hart AA et al. Value of resection of pulmonary metastases in head and neck cancer patients. Head Neck18(4), 311–316 (1996).
   PubMed Web of Science ®Google Scholar
• Nibu K, Nakagawa K, Kamata S et al. Surgical treatment for pulmonary metastases of squamous cell carcinoma of the head and neck. Am. J. Otolaryngol.18(6), 391–395 (1997).
   PubMed Web of Science ®Google Scholar
• Finley RK 3rd, Verazin GT, Driscoll DL et al. Results of surgical resection of pulmonary metastases of squamous cell carcinoma of the head and neck. Am. J. Surg.164(6), 594–598 (1992).
   PubMed Web of Science ®Google Scholar
• Chen F, Sonobe M, Sato K et al. Pulmonary resection for metastatic head and neck cancer. World J. Surg.32(8), 1657–1662 (2008).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Remenar E, van Herpen C et al.; for the EORTC 24971/TAX323 Study Group. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med.357, 1695–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med.357, 1705–1715 (2007).
   PubMed Web of Science ®Google Scholar
• Pointreau Y, Garaud P, Chapet S et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst.101, 498–506 (2009).
   PubMed Web of Science ®Google Scholar
• Gibson MK, Li Y, Murphy B et al.; Eastern Cooperative Oncology Group. Randomized Phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol.15, 3562–3567 (2005).
   Google Scholar
• Forastiere AA, Metch B, DE Schuller et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J. Clin. Oncol.10, 1245–1251 (1992).
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med.359, 1116–1127 (2008).
   PubMed Web of Science ®Google Scholar
• Campbell JB, Dorman EB, McCormick M et al. A randomized Phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluoro-uracil in end-stage head and neck cancer. Acta Otolaryngol.103(5–6), 519–528 (1987).
   PubMedGoogle Scholar
• Morton RP, Rugman F, Dorman EB et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial Phase III controlled trial. Cancer Chemother. Pharmacol.15(3), 283–289 (1985).
   PubMed Web of Science ®Google Scholar
• Eisenberger M, Hornedo J, Silva H et al. Carboplatin (NSC–241–240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J. Clin. Oncol.4, 1506–1509 (1986).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Bertino JR, Goffinet DR, Fee WE, Goode RL. 24-hour infusion of cis-platinum in head and neck cancers. Cancer42(5), 2135–2140 (1978).
   PubMed Web of Science ®Google Scholar
• Jacobs C, Lyman G, Velez-Garcia E et al. A Phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol.10, 257–263 (1992).
   PubMed Web of Science ®Google Scholar
• Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CARBO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a Phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann. Oncol.5, 521–526 (1994).
   PubMed Web of Science ®Google Scholar
• Veronesi A, Zagonel V, Tirelli U et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J. Clin. Oncol.3, 1105–1108 (1985).
   PubMed Web of Science ®Google Scholar
• Hong WK, Schaefer S, Issell B et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer52, 206–210 (1983).
   PubMed Web of Science ®Google Scholar
• Pitman SW, Miller D, Weichselbaum R. Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope88, 632–638 (1978).
   PubMedGoogle Scholar
• Taylor SG 4th, McGuire WP, Hauck WW, Showel JL, Lad TE. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J. Clin. Oncol.2(9), 1006–1011 (1984).
   PubMed Web of Science ®Google Scholar
• Woods RL, Fox RM, Tattersall MH. Methotrexate treatment of advanced head and neck cancers: a dose response evaluation. Cancer Treat. Rep.65(Suppl. 1), 155–159 (1981).
   PubMedGoogle Scholar
• Stewart JS, Cohen EE, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.27, 1864–1871 (2009).
   PubMed Web of Science ®Google Scholar
• Machiels JP, Subramian S, Ruzsa A et al. An open-label, randomized Phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFR) antibody, versus best supportive care in patients with non-curable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based therapy. J. Clin. Oncol.28, 7 (2010).
   Google Scholar
• Schornagel JH, Verweij J, de Mulder PH et al. Randomized Phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J. Clin. Oncol.13(7), 1649–1655 (1995).
   PubMed Web of Science ®Google Scholar
• Pivot X, Raymond E, Laguerre B et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer85(5), 649–655 (2001).
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Shank D, Neuberg D, Taylor SG 4th, DeConti RC, Adams G. Final report of a Phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer82(11), 2270–2274 (1998).
   PubMed Web of Science ®Google Scholar
• Langer CJ, Li Y, Jennings T, DeConti RC et al.; Eastern Cooperative Oncology Group. Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group. Cancer Invest.22(6), 823–831 (2004).
   PubMed Web of Science ®Google Scholar
• Fayette J, Montella A, Chabaud S et al. Paclitaxel is effective in relapsed head and neck squamous cell carcinoma: a retrospective study of 66 patients at a single institution. Anticancer Drugs21(5), 553–558 (2010).
   PubMedGoogle Scholar
• Grau JJ, Caballero M, Verger E, Monzó M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol.129(11), 1294–1299 (2009).
   PubMed Web of Science ®Google Scholar
• Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J. Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck – EORTC Early Clinical Trials Group. Ann. Oncol.5, 533–537 (2004).
   Google Scholar
• Dreyfuss AI, Clark JR, Norris CM et al. Docetaxel. An active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol.14, 1672–1678 (1996).
   PubMed Web of Science ®Google Scholar
• Couteau C, Chouaki N, Leyvraz S et al. A Phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer81, 457–462 (1999).
   PubMed Web of Science ®Google Scholar
• Cho BC, Keum KC, Shin SJ et al. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck. Cancer Chemother. Pharmacol.65(1), 27–32 (2009).
   PubMed Web of Science ®Google Scholar
• Guardiola E, Peyrade F, Chaigneau L et al. Results of a randomised Phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur. J. Cancer40(14), 2071–2076 (2004).
   PubMed Web of Science ®Google Scholar
• Colevas D. Chemotherapy options for patients with metastaticor recurecurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol.17(2), 644–2652 (2006).
   Google Scholar
• Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group. A randomized Phase II study of ixabepilone (BMS–247550) given daily ×5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann. Oncol.19, 977–983 (2008).
   PubMed Web of Science ®Google Scholar
• Amrein PC, Weitzman SA. Treatment of squamous-cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J. Clin. Oncol.3, 1632–1639 (1985).
   PubMed Web of Science ®Google Scholar
• Kish JA, Weaver A, Jacobs J, Cummings G, Al-Sarraf M. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer53(9), 1819–1824 (1984).
   PubMed Web of Science ®Google Scholar
• Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol.21(3), 311–319 (1994).
   PubMed Web of Science ®Google Scholar
• Schrijvers D, Johnson J, Jiminez U et al. Phase III trial of modulation of cisplatin/5-fluorouracil chemotherapy by interferon α-2b in patients with recurrent and metastatic head and neck cancer. Head and Neck Interferon Cooperative Study group. J. Clin. Oncol.16(3), 1054–1059 (1998).
   PubMed Web of Science ®Google Scholar
• Moosmann P, Egli F, Stahel RA, Jost L. Weekly paclitaxel and carboplatin combination chemotherapy in patients with advanced squamous cell carcinoma of the head and neck. Onkologie26, 568–572 (2003).
   PubMedGoogle Scholar
• Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol.20(6), 1593–1599 (2002).
   PubMed Web of Science ®Google Scholar
• Kucukzeybek Y, Gorumlu G, Karaca B et al. Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer. J. BUON13(2), 199–203 (2008).
   PubMedGoogle Scholar
• Gedlicka C, Formanek M, Selzer E et al. Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Oncology63, 145–150 (2002).
   PubMed Web of Science ®Google Scholar
• Clark JI, Hofmeister C, Choudhury A et al. Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer92, 2334–2340 (2001).
   PubMed Web of Science ®Google Scholar
• Baur M, Kienzer HR, Schweiger J et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a Phase II trial. Cancer94, 2953–2958 (2002).
   PubMed Web of Science ®Google Scholar
• Basaran M, Bavbek SE, Gullu I et al. A Phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer. J. Chemother.14, 207–213 (2002).
   PubMed Web of Science ®Google Scholar
• Adamo V, Ferraro G, Pergolizzi S et al. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncol.40, 525–531 (2004).
   PubMed Web of Science ®Google Scholar
• Pivot X, Cals L, Cupissol D et al. Phase II trial of a paclitaxel–carboplatin combination in recurrent squamous cell carcinoma of the head and neck. Oncology60(1), 66–71 (2001).
   PubMedGoogle Scholar
• Ferrari D, Fiore J, Codecà C et al. A Phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer. Anticancer Drugs20(3), 185–190 (2009).
   PubMed Web of Science ®Google Scholar
• Espinosa E, Zamora P, Milla A et al. A Phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck24, 1054–1059 (2002).
   PubMedGoogle Scholar
• Argiris A, Buchanan A, Brockstein B et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a Phase 2 trial of the Eastern Cooperative Oncology Group. Cancer115(19), 4504–4513 (2009).
   PubMed Web of Science ®Google Scholar
• Genet D, Cupissol D, Calais G et al. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a Phase II multicenter study. Am. J. Clin. Oncol.27, 472–476 (2004).
   PubMedGoogle Scholar
• Colevas AD, Adak S, Amrein PC, Barton JJ, Costelo R, Posner MR. A Phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck. Ann. Oncol.11, 535–539 (2000).
   PubMed Web of Science ®Google Scholar
• Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck29(1), 47–51 (2007).
   PubMed Web of Science ®Google Scholar
• Airoldi M, Cattel L, Milla P, Pedani F, Garzaro M, Dosio F. Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interaction. Anticancer Res.28(4C), 2519–2527 (2008).
   PubMedGoogle Scholar
• Labourey JL, Cupissol D, Calais G et al. Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a Phase II multicenter study. Am. J. Clin. Oncol.30(3), 278–282 (2007).
   PubMed Web of Science ®Google Scholar
• Shin DM, Glisson BS, Khuri FR et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J. Clin. Oncol.16, 1325–1330 (1998).
   PubMed Web of Science ®Google Scholar
• Shin DM, Khuri FR, Glisson BS et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer91, 1316–1323 (2001).
   PubMed Web of Science ®Google Scholar
• Janinis J, Papadakou M, Xidakis E et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a Phase II feasibility study. Am. J. Clin. Oncol.3, 128–131 (2000).
   Google Scholar
• Hitt R, Jimeno A, Millán JM, Castellano D, Cortés-Funes H. Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. Cancer101(4), 768–775 (2004).
   PubMedGoogle Scholar
• Wells N, Murphy B, Dietrich M, Forastiere AA, Li Y, Cella D. Quality of life and pain assessment for head and neck cancer patients treated on E1395. J. Clin. Oncol.21 (2002) (Abstract 907).
   Google Scholar
• Forastiere AA, Leong T, Rowinsky E et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J. Clin. Oncol.15, 1088–1095 (2001).
   Google Scholar
• Yarden Y. The EGFR family and its ligand in human cancer: signaling mechanisms and therapeutic opportunities. Eur. J. Cancer37, 3–8 (2001).
   PubMed Web of Science ®Google Scholar
• Baselga J. The EGFR as a target for anticancer therapy–focus on cetuximab. Eur. J. Cancer16–22 (2001).
   Google Scholar
• Grünwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst.18, 851–867 (2003).
   Google Scholar
• Milas L, Mason K, Hunter et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res.6, 701–708 (2000).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Raisch KP, Trummell HQ et al. Enhanced apoptosis with combination C225/radiation treatement serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol.18, 47–53 (2000).
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Argiris A, Ghebremichael M, Gilbert J, Burtness B, Forastiere A. A Phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). J. Clin. Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition). 27(15S), 6011 (2009) (Abstract).
   Google Scholar